KEDRION BIOPHARMA
LIVE

Serial Number

79428966

Owner

KEDRION S.p.A.

Attorney

Lindsay M.R. Jones

Filing Date

Feb 10, 2025

Add to watchlist:

No watchlists yet
View on USPTO

KEDRION BIOPHARMA Trademark

Serial Number: 79428966 • Registration: 8279000

KEDRION BIOPHARMA is a trademark filed by KEDRION S.p.A. on February 10, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

KEDRION S.p.A. (10 trademarks)

Loc Ai Conti 55051 Castelvecchio Pascoli
Barga (Lucca) , IT

Entity Type: 03

Trademark Details

Filing Date

February 10, 2025

Registration Date

June 2, 2026

Published for Opposition

April 14, 2026

Goods & Services

Scientific and technological services, namely, research, analysis, and testing, in the field of pharmaceuticals, medical disorders and the treatment of medical disorders, and clinical trials, ; medical and pharmacological research services; providing information and data in relation to medical research and development in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of medical disorders and their treatment; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical research; biological research, clinical research and medical research in the field of pharmaceuticals and clinical trials; design and development of computer software for use with medical technology; scientific research on the subject of pharmaceuticals; providing information technology services for the pharmaceutical and healthcare industries; providing information about the results of clinical trials for pharmaceutical products

Medical services and small molecule therapy services; medical consultancy in relation to medical and pharmaceutical field; health center services for therapeutical purposes

Pharmaceutical products for the treatment of primary and secondary immunodeficiency disorders, coagulation disorders, autoimmune diseases treatable with immunoglobulins, and other conditions treatable with plasma derived therapies, biologic therapies, and small molecules therapies; Pharmaceutical preparations for the treatment of primary and secondary immunodeficiency disorders, coagulation disorders, autoimmune diseases treatable with immunoglobulins, and other conditions treatable with plasma derived therapies, biologic therapies, and small molecules therapies

Business management; business administration; office functions in the nature of regulatory documentation management for biopharmaceutical activities and pharmaceutical regulatory compliance for others; Business administration in the nature of sales administration

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 2, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 2, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 14, 2026 NPUB
PUBLISHED FOR OPPOSITION
Apr 14, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 8, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 18, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 18, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 18, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 18, 2026 TROA
REFUSAL PROCESSED BY IB
Oct 10, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 24, 2025 RFCS
REFUSAL PROCESSED BY MPU
Sep 24, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 12, 2025 RFCR
NON-FINAL ACTION WRITTEN
Aug 11, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 2, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 1, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 1, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 31, 2025 REPR